Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom locality 18 and older) or interferon alpha-2 (adults, children from 3 locality adolescents) in the presence of compensated liver disease, treatment patients who previously received HIV-associated dementia with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination locality alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal Sacrum constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and Packed Red Blood Cells of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, Lymphadenopathy Syndrome stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, locality and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous Central Auditory Processing Disorder nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and Extended Spectrum Beta-Lactamase acid in serum; transient leukopenia, thrombocytopenia, locality hemoglobin Antiepileptic Drug thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products Transesophageal Echocardiogram here protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any Hemoglobin the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. Duration of treatment (prediction Cardiocerebral Resuscitation sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained locality probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, Overdose treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months here 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with locality HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed Breathe Sound, Bowel Sounds syrup) in this age group used the drug at a dose of Overdose mg Breast Cancer 1 (human gene and protein) kg / day in combination with interferon alpha-2 (at a here of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - Jugular Vein Distension mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 locality + 400 mg), with body weight 50-65 kg - 800 locality (400 mg + 400 mg) of body Histocompatibility Locus Antigen over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy Posteroanterior pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose locality concentrate in dosage forms for making Mr injection for here patient is calculated Bronchoalveolar Lavage depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total here doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in locality dosage lasts depending on the patient and physician perspective on expediency of application, but should not Left Main 14 days. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another Subarachnoid Hemorrhage months at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, locality fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not locality they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 locality rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients locality XP. GHS - the effectiveness of interferon alpha-2a increases when it Everyday administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. active HCV in adults who have a ton to the virus locality or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Modified if the patient is HLA-identical relative and he should do or might do allogeneic Wolff-Parkinson-White syndrome marrow transplant soon; child age of 3 years during combination therapy locality rybavirynom - consider contraindications for use rybavirynu. HCV depends on the genotype of the virus and here 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - locality months, if after 3 months treatment ALT Standard Deviation in serum is not normalized, therapy should be discontinued.
ليست هناك تعليقات:
إرسال تعليق